Galderma delivers 2024 record net sales of 4.410 billion USD, up 9.3% year-on-year at constant currency1, and record Core EBITDA of 1.031 billion USD, while preparing to accelerate its growth trajectory into 2025 and beyond Press release
AAD 2025: Galderma to present extensive updates from across its dermatology portfolio, demonstrating its category leadership and strong momentum Press release
Galderma’s Nemluvio® (nemolizumab) granted marketing authorization in the United Kingdom and Switzerland for moderate-to-severe atopic dermatitis and prurigo nodularis Press release
Galderma’s Nemluvio® (nemolizumab) approved in the European Union for moderate-to-severe atopic dermatitis and prurigo nodularis Press release
IMCAS 2025: New Galderma phase IIIb data reinforce rapid onset and long-lasting aesthetic improvement with RelabotulinumtoxinA (Relfydess™) Press release
Galderma demonstrates Injectable Aesthetics leadership in medication-driven weight loss with new research and first international consensus-based guidelines Press release
IMCAS 2025: Galderma’s broad presence and new data on recently launched products Restylane® SHAYPE™ and Relfydess® reaffirm its category leadership Press release
Galderma premieres positive interim results demonstrating the efficacy of its Injectable Aesthetics portfolio in addressing facial volume loss as a result of medication-driven weight loss Press release
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis Press release
CHMP recommends approval of Galderma’s nemolizumab for moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union Press release
